Candel Therapeutics (CADL) Current Assets (2020 - 2025)

Candel Therapeutics has disclosed Current Assets across 6 years of filings, most recently posting $121.4 million for Q4 2025.

• Current Assets for Q4 2025 came in at $121.4 million, up 16.94% year-over-year; the trailing twelve-month figure through Dec 2025 was $121.4 million (up 16.94% YoY), and the FY2025 annual result was $121.4 million, up 16.94% from the prior year.
• Current Assets came in at $121.4 million for Q4 2025 at Candel Therapeutics, up from $90.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $121.4 million in Q4 2025 to a low of $18.1 million in Q3 2024.
• The 5-year median for Current Assets is $79.1 million (2022), against an average of $69.0 million.
• Across the five-year window, Current Assets tumbled 59.9% in 2024 and soared 398.39% in 2025, its largest moves.
• Candel Therapeutics' Current Assets stood at $84.9 million in 2021, then retreated by 15.3% to $71.9 million in 2022, then slumped by 48.85% to $36.8 million in 2023, then soared by 182.1% to $103.8 million in 2024, then gained by 16.94% to $121.4 million in 2025.
• The last three Current Assets figures came in at $121.4 million (Q4 2025), $90.1 million (Q3 2025), and $103.6 million (Q2 2025), per Business Quant data.